Epigenetics Drugs And Diagnostic Technologies Market to Receive overwhelming hike in Revenues by 2020–2027

The broad epigenetics drugs and diagnostic technologies market has been sub-grouped into drugs mechanism of action and technology type. the geographical segmentation which mainly focuses on current and forecast demand for epigenetics drugs and diagnostic technologies in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

By Drugs Mechanism Of Action

  • DNMT Inhibitors
  • Azacitidine (Vidaza)
  • Decitabine (Dacogen)
  • HDAC Inhibitors
  • Vorinostat (Zolinza)
  • Romidepsin (Istodax)

By Technology Types

  • DNA Methylation
  • Chromatin Immunoprecipitation (ChIP) Technology

The increasing geriatric population and rising oncology and non-oncology disorders are driving the market growth. Also, the high prevalence of cancer with advancement is screening techniques is further fuelling market growth. In addition, reduction in sequential cost and time is another factor pushing the market growth. Though, the funding and support of the organizations such as NIH and NCI for R&D are expected to boost the market growth in the forecast period. However, problems associated with quality may hamper market growth.

The key players in the epigenetics drugs and diagnostic technologies market include 4SC AG, Acetylon Pharmaceuticals, Inc., Astex Pharmaceuticals Inc., Celenge, CellCentric Ltd., Celleron Therapeutics Ltd., Chroma Therapeutics Ltd., Eisai Pharmaceuticals, EnVivo Pharmaceuticals Inc., Epigentek Group Inc., Epizyme, Inc. Illumina Inc., MDxHealth, Merck, Merck & Company Inc., Novartis International AG, Oncolys BioPharma Inc., Pharmacyclics, Promega Corporation, Spectrum Pharmaceuticals, Syndax Pharmaceuticals, Inc., Topotarget A/S, and Valirx Plc.

Source: https://www.valuemarketresearch.com/report/epigenetics-drugs-and-diagnostic-technologies-market

Leave a Reply

Your email address will not be published. Required fields are marked *

Social Media Auto Publish Powered By : XYZScripts.com